United Therapeutics (NASDAQ:UTHR) Price Target Raised to $475.00 at UBS Group

United Therapeutics (NASDAQ:UTHR) had its price target upped by UBS Group from $415.00 to $475.00 in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently commented on UTHR. Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 30th. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Price Performance

UTHR stock opened at $366.61 on Wednesday. The company’s 50 day simple moving average is $370.83 and its 200-day simple moving average is $351.77. United Therapeutics has a 52-week low of $208.62 and a 52-week high of $417.82. The firm has a market capitalization of $16.37 billion, a P/E ratio of 16.10, a P/E/G ratio of 1.05 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.38 earnings per share. Sell-side analysts predict that United Therapeutics will post 25.22 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 7,800 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. This represents a 52.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 142,422 shares of company stock worth $53,498,732. 11.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the company. Tri Locum Partners LP bought a new stake in United Therapeutics during the second quarter worth about $15,959,000. JPMorgan Chase & Co. grew its position in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Franklin Resources Inc. increased its holdings in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Bridgewater Associates LP grew its stake in shares of United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock valued at $22,130,000 after purchasing an additional 49,003 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of United Therapeutics by 6.4% in the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock valued at $24,585,000 after purchasing an additional 4,145 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.